EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity

Seiichi Okabe, Yuya Arai, Akihiko Gotoh iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252111800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Seiichi Okabe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Tokyo Medical University, Tokyo 160-0023, Japan. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, SARS-CoV-2, Vitamin K 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by excessive proliferation of myeloid cells. The COVID-19 pandemic has raised concerns regarding the impact of SARS-CoV-2 on patients with malignancies, particularly those with CML. This study aimed to investigate the effects of SARS-CoV-2 proteins on CML cell viability and the protective role of vitamin K2 (VK2) in conjunction with imatinib. Experiments conducted on K562 CML cells demonstrated that the SARS-CoV-2 envelope protein induces cytotoxicity and activates caspase 3/7, which are key markers of apoptosis. VK2 mitigated these cytotoxic effects and decreased cytokine production while inhibiting colony formation. Furthermore, the combination of VK2 with imatinib significantly reduced cellular proliferation, diminished mitochondrial membrane potential, and markedly suppressed colony formation. These findings suggest that VK2 protects CML cells from SARS-CoV-2-induced cytotoxicity and enhances the therapeutic efficacy of imatinib, presenting a potential strategy to improve CML treatment during the COVID-19 pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSARS-CoV-2Vitamin K 2ApoptosisCOVID-19HumansK562 CellsViral Envelope ProteinsCell SurvivalMembrane Potential, MitochondrialCell ProliferationDrug SynergismAntineoplastic AgentsCOVID-19 Drug Treatment

Stichwörter der Autor:innen

CMLSARS-CoV-2envelope proteinimatinibvitamin K2

Substanzen

Imatinib MesylateVitamin K 2Viral Envelope ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Hematology, Tokyo Medical University, Tokyo 160-0023, Japan.

ORCID-Profile: Akihiko Gotoh

Zitieren

APA

Okabe, S., Arai, Y., & Gotoh, A. (2024). Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252111800

Vancouver

Okabe S, Arai Y, Gotoh A. Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252111800

BibTeX
@article{Okabe2024,
  author = {Okabe, Seiichi and Arai, Yuya and Gotoh, Akihiko},
  title = {Vitamin K2 Protects Against SARS-CoV-2 Envelope Protein-Induced Cytotoxicity in Chronic Myeloid Leukemia Cells and Enhances Imatinib Activity},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252111800}
}
Kostenlos starten →